Clinical trial

Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

NCT01547104

Study summary

ClinicalTrials.gov

Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Linagliptin Normalized identity: linagliptin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Glimepiride Normalized identity: glimepiride View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2012-04-01

PhasePHASE4

Conditions

Diabetes Mellitus Type 2unresolved

Interventions

LinagliptinDRUG · verified · RxNorm: linagliptin

GlimepirideDRUG · verified · RxNorm: glimepiride

Sponsors & collaborators

Marcus Borchertlead sponsor

ikfe-CRO GmbHcollaborator

Boehringer Ingelheimcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01547104 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.